{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:21Z","timestamp":1786650081349,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the correlation of ABO blood types and clinicopathological characteristics of patients with ureteral transitional cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In our study, an entire cohort of 239 patients who were pathological diagnosed as ureteral transitional cell carcinoma (TCC) between February 2002 and March 2010 were reviewed retrospectively. Variables including demographic features, tumor grades, tumor stages, type of surgery and number of tumors as well as ABO blood types status were evaluated. The relationship between the ABO blood group and clinicopathological variables was assessed by Chi-squared analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The ratio of male to female was 1: 1.12. The median age at diagnosis was 68.5 years. A total of 111 neoplasms located in the right ureter. A total of 218 patients had radical nephroureterectomy (RNU). Multifocality was observed in 32 patients. The pathology was as follow: Grade 1 (seven cases), Grade 2 (110 cases) and Grade 3 (122 cases); Ta and T1 (83 cases), T2-T4 (156 cases). The distribution of ABO blood types was A, B, O and AB in 70 (29.3%), 76 (31.8%), 66 (27.6%) and 27 (11.3%), respectively. There were no significant differences in the clinicopathological variables among individuals with different ABO blood types. In a subgroup analysis, B and O group showed a worse tumor stage compared with A and AB groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>B and O blood types are at higher risk of muscle invasive ureteral TCC as compared with A and AB blood types. We suggest ABO blood types to be taken into consideration when urologists select therapeutic schemes for individuals with ureteral TCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.146085","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T05:33:49Z","timestamp":1469511229000},"page":"601-604","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Association of ABO blood types and clinicopathological features of ureteral transitional cell carcinoma in a single-center in China"],"prefix":"10.4103","volume":"12","author":[{"given":"Haichao","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2010.12.042","article-title":"European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update","volume":"59","author":"Roupr\u00eat","year":"2011","journal-title":"Eur Urol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","article-title":"Nephroureterectomy and segmental ureterectomy inthe treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients","volume":"45","author":"Lughezzani","year":"2009","journal-title":"Eur J Cancer"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.juro.2009.07.035","article-title":"Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma","volume":"182","author":"Isbarn","year":"2009","journal-title":"J Urol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-5347(05)67135-2","article-title":"Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys","volume":"164","author":"Chen","year":"2000","journal-title":"J Urol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.juro.2010.02.005","article-title":"Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma","volume":"183","author":"Gadzinski","year":"2010","journal-title":"J Urol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","article-title":"European Association of Urology. European guidelines on upper tract urothelial carcinomas: 2013 update","volume":"63","author":"Roupr\u00eat","year":"2013","journal-title":"Eur Urol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.urology.2007.06.1106","article-title":"Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma","volume":"70","author":"Cho","year":"2007","journal-title":"Urology"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000475147","article-title":"Computed tomography for detection and staging of transitional cell carcinoma of the upper urinary tract","volume":"27","author":"Planz","year":"1995","journal-title":"Eur Urol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0090-4295(00)00800-1","article-title":"Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma","volume":"56","author":"Scolieri","year":"2000","journal-title":"Urology"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1378\/chest.13-1962","article-title":"ABO blood type A is associated with increased risk of ARDS in whites following both major trauma and severe sepsis","volume":"145","author":"Reilly","year":"2014","journal-title":"Chest"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1007\/s13277-014-1960-7","article-title":"The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: A retrospective study from China","volume":"35","author":"Sun","year":"2014","journal-title":"Tumour Biol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.7314\/APJCP.2014.15.3.1415","article-title":"ABO blood group in oral cancer: A first case-control study in a defined group of Iranian patients","volume":"15","author":"Mortazavi","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.7314\/APJCP.2012.13.10.5091","article-title":"ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of south-east Siberia","volume":"13","author":"Yuzhalin","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.juro.2013.11.106","article-title":"Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer","volume":"191","author":"Klatte","year":"2014","journal-title":"J Urol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1111\/j.1464-410X.2012.11554.x","article-title":"Elective segmental ureterectomy for transitional cell carcinoma of the ureter: Long-term follow-up in a series of 73 patients","volume":"110","author":"Simonato","year":"2012","journal-title":"BJU Int"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.juro.2009.12.018","article-title":"Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter","volume":"183","author":"Jeldres","year":"2010","journal-title":"J Urol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.urology.2012.12.059","article-title":"Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma","volume":"81","author":"Bagrodia","year":"2013","journal-title":"Urology"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.urolonc.2011.07.011","article-title":"Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma","volume":"31","author":"Messer","year":"2013","journal-title":"Urol Oncol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.juro.2010.03.030","article-title":"Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma","volume":"184","author":"Brien","year":"2010","journal-title":"J Urol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2183\/pjab1945.27.455","article-title":"On a specific enzyme which decomposes group A substances","volume":"27","author":"Iseki","year":"1951","journal-title":"Proc Jpn Acad"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1111\/j.1464-410X.2012.11366.x","article-title":"ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma","volume":"110","author":"Kaffenberger","year":"2012","journal-title":"BJU Int"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"20790","DOI":"10.1016\/S0021-9258(17)45285-9","article-title":"Blood group A glycolipid antigen expression in kidney, ureter, kidney artery, and kidney vein from a blood group A1Le (a-b+) human individual. Evidence for a novel blood group A heptaglycosylceramide based on a type 3 carbohydrate chain","volume":"265","author":"Holgersson","year":"1990","journal-title":"J Biol Chem"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/jcp.39.11.1165","article-title":"Expression of blood group antigens in urinary tract tumours: Prospective fluorescence study using cryostat sections of fresh frozen tissues","volume":"39","author":"Thorpe","year":"1986","journal-title":"J Clin Pathol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/bmj.1.4814.799","article-title":"A relationship between cancer of stomach and the ABO blood groups","volume":"11","author":"Aird","year":"1953","journal-title":"Br Med J"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0090-4295(83)90410-7","article-title":"Detection of cell surface antigen in cancer of renal pelvis and ureter","volume":"22","author":"Lippert","year":"1983","journal-title":"Urology"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:52Z","timestamp":1786647712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.146085","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}